University of Witten/Herdecke, Faculty of Medicine, Friedrichstrasse 3/4, 37073 Goettingen, Germany.
Expert Rev Med Devices. 2010 Jan;7(1):21-6. doi: 10.1586/erd.09.56.
Allergic rhinitis, although not life threatening, significantly affects the quality of the patient's daily life. The three major steps in the treatment of the condition are avoidance of allergens, treatment of symptoms (in particular, antihistaminics and topical nasal corticosteroids) and specific immunotherapy. Avoidance of the allergen is usually not possible and symptom relief is often limited, despite the availability of a number of pharmacological options. Specific immunotherapy demands a high level of cooperation on the part of the patient for at least 3 years. Endonasal phototherapy with the Rhinolight device (Rhinolight Ltd, Szeged, Hungary) for the treatment of immunoglobulin E-mediated allergic rhinitis is a new option that utilizes the immunosuppressive effects of UV radiation. The method directs a combination of UV-B (5%), UV-A (25%) and visible light (70%) into the nasal cavity, and its effectiveness has been demonstrated in one double-blind, placebo-controlled study. The results of additional studies have been presented at various medical conferences and in abstracts. Reports in the literature confirm that phototherapy is a well-established and successful treatment of atopic dermatitis and other skin diseases.
变应性鼻炎虽然不会危及生命，但会显著影响患者的日常生活质量。该疾病的治疗有三个主要步骤：避免过敏原、治疗症状（特别是抗组胺药和局部鼻腔皮质类固醇）和特异性免疫疗法。通常无法避免过敏原，尽管有许多药物选择，但症状缓解往往有限。特异性免疫疗法需要患者至少合作 3 年。鼻内光疗是一种新的治疗方法，使用 Rhinolight 设备（Rhinolight Ltd，匈牙利塞格德），利用紫外线辐射的免疫抑制作用，治疗免疫球蛋白 E 介导的变应性鼻炎。该方法将 UV-B（5%）、UV-A（25%）和可见光（70%）组合导入鼻腔，其有效性已在一项双盲、安慰剂对照研究中得到证实。其他研究的结果已在各种医学会议和摘要中提出。文献中的报告证实，光疗是一种成熟且成功的特应性皮炎和其他皮肤病的治疗方法。
